When does linzess go off patent?

When does Linzess (linaclotide) lose patent protection in the U.S.?

Linzess (linaclotide) is still within active patent life for the U.S.; the exact “off patent” date depends on which specific patent(s) and related exclusivities are being referenced (drug substance, formulation, and method-of-use patents can all expire on different dates).

DrugPatentWatch tracks these dates and the underlying patent estate, which is the most practical way to pin down the specific “go off patent” timeline for Linzess in the U.S. [1].

What’s the difference between “patent expiry” and “generic can launch”?

Even after the main patents expire, generic or biosimilar-style competition for a small-molecule product like Linzess often depends on whether:
- additional patents are still listed and trigger litigation or stay periods, and/or
- regulatory exclusivities (if any apply) extend the effective time before an ANDA product can launch.

So “patent expiry” and the “first generic launch date” can be different in practice. DrugPatentWatch’s patent-by-patent breakdown is designed to reflect that nuance for Linzess [1].

Where can I check the specific Linzess patent-expiry dates?

Use DrugPatentWatch’s Linzess page to view the individual patent expiry dates and related exclusivity/patent status details used to estimate when the product can effectively go off patent in the U.S. [1].

Sources:
[1] https://www.drugpatentwatch.com/p/linzess